GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (NAS:PTCT) » Definitions » Cash Flow from Investing

PTCT (PTC Therapeutics) Cash Flow from Investing : $-25 Mil (TTM As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2025, PTC Therapeutics spent $2 Mil on purchasing property, plant, equipment. It gained $0 Mil from selling property, plant, and equipment. It spent $0 Mil on purchasing business. It gained $0 Mil from selling business. It spent $328 Mil on purchasing investments. It gained $146 Mil from selling investments. It paid $1Mil for net Intangibles purchase and sale. And it paid $0 Mil for other investing activities. In all, PTC Therapeutics spent $184 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2025.


PTC Therapeutics Cash Flow from Investing Historical Data

The historical data trend for PTC Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Cash Flow from Investing Chart

PTC Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -561.55 219.18 290.18 -176.74 44.18

PTC Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -114.93 -65.92 -42.68 267.71 -184.36

PTC Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

PTC Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2024 is calculated as:

PTC Therapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2025 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PTC Therapeutics  (NAS:PTCT) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

PTC Therapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2025 was $-2 Mil. It means PTC Therapeutics spent $2 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

PTC Therapeutics's sale of property, plant, equipment for the three months ended in Mar. 2025 was $0 Mil. It means PTC Therapeutics gained $0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

PTC Therapeutics's purchase of business for the three months ended in Mar. 2025 was $0 Mil. It means PTC Therapeutics spent $0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

PTC Therapeutics's sale of business for the three months ended in Mar. 2025 was $0 Mil. It means PTC Therapeutics gained $0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

PTC Therapeutics's purchase of investment for the three months ended in Mar. 2025 was $-328 Mil. It means PTC Therapeutics spent {stock_data.stock.currency_symbol}}328 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

PTC Therapeutics's sale of investment for the three months ended in Mar. 2025 was $146 Mil. It means PTC Therapeutics gained $146 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

PTC Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2025 was $-1 Mil. It means PTC Therapeutics paid $1 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

PTC Therapeutics's cash from discontinued investing activities for the three months ended in Mar. 2025 was 0 Mil. It means PTC Therapeutics paid $0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

PTC Therapeutics's cash from other investing activities for the three months ended in Mar. 2025 was $-0 Mil. It means PTC Therapeutics paid $0 Mil for other investing activities.


PTC Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

Traded in Other Exchanges
Address
500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Executives
Mark Elliott Boulding officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Matthew B. Klein officer: Chief Development Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Lee Scott Golden officer: Chief Medical Officer 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Eric Pauwels officer: Chief Business Officer 550 HILLS DRIVE, BEDMINSTER NJ 07921
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Allan Steven Jacobson director PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Neil Gregory Almstead officer: EVP Research Pharma Ops & Tech C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pierre Gravier officer: CHIEF FINANCIAL OFFICER C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Christine Marie Utter officer: Principal Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Michael Schmertzler director 110 WASHINGTON STREET, SUITE 1300, CONSHOHOCKEN PA 19428
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Bell William F. Jr. director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
David P Southwell director C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421